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Abstract
Objective—Patient antiretroviral (ARV) therapy knowledge is essential for regimen adherence,
successful therapeutic response, and minimization of resistance evolution. Moreover, a complete
and accurate patient ARV history is needed to construct efficacious and tolerable future regimens.
In this study we assessed the ability of HIV-infected patients receiving care in a university
infectious diseases clinic to accurately recall current and past ARVs.
Methods—A convenience sample (n = 205) of UNC HIV Clinical Cohort participants (n = 1840)
completed a comprehensive in-person interview. Patients were asked about current and ever ARV
use and were provided proprietary and generic ARV names and photographs. Self-reported
sensitivity for current and ever ARV use (proportion that correctly identified all recorded ARVs),
was calculated using the medical record as the gold standard.
Results—One hundred and eighty-five patients had received ARVs at some point after
enrollment in the cohort study (ever users). For current ARV use (n = 138), self-reported
sensitivity was 63% (95% CI: 54–71). For ever use (n = 185), sensitivity was 18% (95% CI: 13–
24).
Conclusion—Self-reported cumulative ARV use is not accurate. Since HIV-infected patients are
prescribed a number of medications over their treatment course, it is necessary to develop new
medication reconciliation techniques that are not dependent on patient memory or knowledge in
order to improve patient outcomes.
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Combinations of currently approved antiretroviral (ARV) medications can effectively
suppress HIV viral replication, even in the presence of multidrug resistant variants.1–3
Although the durability of an individual patient’s first ARV regimen is increasing,4,5
patients switch ARVs for a multitude of reasons, including toxicity and virologic failure. In
one study, almost one-fifth of patients received their fourth ARV regimen after just 4 years
from initiating therapy,6 and as many as 10–20% of HIV-infected patients in care may
harbor ARV drug resistance to all three commonly used ARV drug classes.7,8 Since
virologic failure and ARV drug mutations are strongly related to progression to an AIDS
defining clinical event and death,8 increasing the durability of each ARV regimen is a
critical clinical goal.
One of the primary components of successful sustained virologic response to ARV therapy
is maintaining adequate adherence.9–13 ARV therapy adherence is associated with a number
of patient socio-demographic, behavioral, and clinical factors, including ARV
knowledge.9,14–16 Although ARV knowledge may affect clinical outcomes, in part through
its effect on adherence, little is known about patient knowledge of the ARVs they are
currently receiving or those they have received in the past.17 Successful treatment of patients
who have had previous therapy and virologic rebound is also dependent on selection of the
most active, well tolerated regimen for an individual patient.18 Resistance testing provides
important information, however, accurate treatment histories may be equally important as a
current resistance test may only reveal mutations selected by the patient’s current regimen.
In addition, patients may present off therapy when resistance testing is less helpful.
Knowledge of ARV tolerability also impacts regimen selection. For all these reasons, an
accurate ARV treatment history is extremely important. Furthermore, as HIV patients are
often transient, visiting many different providers over their treatment course, patient report
may be a clinician’s primary source for ARV treatment history.
Studies investigating patient knowledge of non-ARV medication use has suggested that
many patients may have trouble recalling the medications they are taking.19–22 Therefore,
we designed this study to assess the sensitivity and accuracy of patient self-report of ARV
use, including current and prior use. We also assessed whether any patient demographic or
clinical characteristics were associated with improved ARV self-report.
METHODS
Study population
A convenience sample (n = 205) of UNC CFAR HIV Clinical Cohort study participants (n =
1840) were approached by clinic staff to also complete an in-person interview between 1999
and 2006, with only two individuals completing the interview in 1999 and the remainder
completing the interview after January 2001. The 177 item ongoing interview addresses
topics outside of the patients’ normal clinical care and surveys patients on clinical,
behavioral and socio-demographic matters related to their HIV infection. On specific
interview days, study staff approached all patients who were consented to participate in the
UNC CFAR HIV Clinical Cohort study and gave permission for study staff to approach
them for additional research activities. Interviews were conducted on all days of the week so
as to interview patients seen by all providers. No exclusion criteria were used to select
patients who completed the interview. All patients receiving HIV care, irrespective of
whether or not they were receiving antiretroviral therapy, who provided informed consent to
participate in the UNC CFAR HIV Clinical Cohort were eligible to complete the interview.
Patients who completed the interview were representative of the overall cohort. The UNC
CFAR HIV Clinical Cohort study enrolls HIV-1-infected patients receiving primary HIV
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care at a large tertiary medical center in the Southeastern United States.23 Cohort data
consists of all institutionally available electronic patient records and periodic standardized
medical record reviews, including detailed ARV data.
Study measures
As part of the in-person interview, patient self-reported ARV use was assessed relying on
two separate questions, one for “current use” and one for “ever use”. To facilitate recall,
proprietary and generic names accompanied by photographs of the medications were
provided. Interview administrators did not provide any additional information to the patient
pertaining to ARV use (e.g., dosing, administration requirements, or side effects). The
interview instrument was updated over time to account for the availability of new ARVs.
The medical record was considered the ‘Gold Standard’. Ever ARV use was defined as any
use prior to and including the interview date. Current use was defined as use on the date of
the interview. A correct identification of a fixed dose combination (FDC) medication
included the patient naming either the FDC or each drug entity contained within the FDC.
For example, a patient who self-reports zidovudine and lamivudine would be classified as
having correct recall for the drug entity Combivir® (a combination of zidovudine and
lamivudine). Similarly, a patient who self-reports Combivir® would be classified as having
correct recall if the medical record indicated that they were taking zidovudine and
lamivudine.
Statistical analysis
ARV self-report and medical record agreement was assessed by comparing patient responses
to the medical record. Perfect ARV self-report was defined as identifying all ARVs recorded
in the clinical record (self-report sensitivity). We performed separate analyses to assess self-
report sensitivity for the ARVs a patient was currently taking and all the ARVs a patient had
ever received. We evaluated whether patient demographic (e.g., sex, age, race, and
education level), clinical (e.g., CD4 cell count, HIV RNA level, and cumulative number of
ARVs), and/or study characteristics (year of interview) were associated with ARV self-
report sensitivity. All current and prior ARVs prescribed were used to calculate the
cumulative number of ARVs per patient with FDCs considered one ARV. Chi-square and
Fisher’s exact tests were used to contrast proportions and the Wilcoxon rank-sum and
Kruskal–Wallis tests were used for continuous variables.
We also assessed the proportion of ARVs a patient correctly named (self-report percent
accuracy), calculated as the number of self-reported ARVs also in the clinical record divided
by the number of ARVs in the clinical record. This was done for both the patients’ current
ARV regimen and their cumulative ARV exposure. We evaluated whether patient
demographic, clinical, and study characteristics were associated with self-report accuracy.
The Kruskal–Wallis and the Wilcoxon rank-sum tests were used to examine differences
among groups. To evaluate the correlation between current and ever percent accuracy, we
calculated the Pearson correlation coefficient (r) and calculated the associated confidence
interval using Fisher’s transformation.
Finally, we evaluated whether ARV self-report and medical record agreement were related
to adherence. Adherence was measured by patient self-report of missed doses within the
previous 3 days as well as the ability to maintain a medication schedule: always, most of the
time, sometimes, rarely or never. The adherence assessment instrument is a modification of
the Adult AIDS Clinical Trials Group adherence assessment as previously described.24 The
instrument was modified using input from clinical staff and other study personnel.
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This study was approved by the Institutional Review Board of The University of North
Carolina at Chapel Hill and all patients included in this study provided written informed
consent to participate. All statistical analyses were conducted using the SAS statistical
package (version 9.1; SAS Institute, Inc., Cary, NC, USA).
RESULTS
Study population
The participants (n = 205) were predominantly black (71%), male (66%), and a median age
of 42 years [interquartile range (IQR): 36–47; Table 1]. Approximately one-third of the
study sample did not complete high school. At the time of the interview, patients had been in
care for an average of 6.7 years, almost one-half had HIV-1 RNA below 400 copies/ml, and
the median CD4 cell count was 407 cells/mm3. Compared to the overall cohort, the study
population had a greater proportion of African-American patients (p = 0.006). Nadir CD4
cell count levels were slightly higher in the study population (p = 0.08), while the peak HIV
RNA values were comparable to the overall cohort (p = 0.98). HIV transmission risk
behaviors in the study sample were similar to the overall cohort.
Twenty (10%) patients were ARV-naïve and an additional 47 (23%) were not taking ARVs
at the time of the interview. Overall patients had received a median of five ARVs (IQR, 2–7;
full range, 0–19) over the course of their ARV treatment. At the time of the interview nearly
all patients receiving ARVs were taking a nucleoside(tide) reverse transcriptase inhibitor
(98%), two-thirds (65%) a protease inhibitor, and 37% a non-nucleoside reverse
transcriptase inhibitor.
Antiretroviral self-report and medical record agreement
Among the 138 patients taking ARVs at the time of the interview, 87 could name all the
ARVs they were receiving (self-report sensitivity: 63%; 95% CI: 54–71). Of the 67 patients
not taking any ARVs according to their medical record, 21% (n = 14) reported taking at least
one ARV (95% CI: 12–33). Self-report sensitivity decreased substantially when we
considered all previously received ARVs. Among the 185 patients who had ever received
ARVs, 33 reported all the ARVs they had ever received for a self-report sensitivity of 18%
(95% CI: 13–24). Of the 20 patients who had never received any ARVs, 30% (n = 6)
reported receiving at least one ARV (95% CI: 12–54).
The only factor that was statistically significantly related to self-report sensitivity of a
current ARV regimen was patient sex. Women were more likely than their male
counterparts to correctly report their current ARV medications (77% vs. 54%; p-value 0.02;
Table 2). In analyses assessing ARV ever use, the number of cumulative ARVs received
was strongly associated with self-report sensitivity. Specifically, 37% of patients who had
received a maximum of four ARVs ever, were able to correctly name all the ARVs they had
received; however, only 2% of patients who had received more than four ARVs in their
lifetime could correctly name all the ARVs they had received (p-value <0.001).
On average, patients were able to name 75% of the ARVs they were currently taking and
43% of the ARVs they had ever received. The cumulative distribution of the self-report
percent accuracy measure was skewed for both cumulative and current use. The majority of
the patients had high self-report percent accuracy for current regimens, and low percent
accuracy for their cumulative regimens. Further, as the number of prior ARVs a patient
received increased, current and cumulative percent accuracy decreased (Figure 1). The
Pearson’s correlation coefficient calculated to examine the correlation between patients’
current and cumulative percent accuracy suggests a positive relationship; as percent
accuracy increased for current regimens, the percent accuracy for cumulative regimens also
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increased (r = 0.46, 95% CI: 0.32–0.58). We did not identify any statistically significant
associations with percent accuracy for current or cumulative ARV use (Table 3). However,
while not statistically significant, the mean percent accuracy for current ARV regimens did
increase over calendar time.
In a sensitivity analysis, we restricted the population to patients who initiated HIV care at
the University of North Carolina Infectious Diseases Clinic. Forty-five percent (n = 92) of
patients did not receive any prior HIV care. The current and cumulative self-report
sensitivity for this sub-group of individuals was 66% (95% CI: 53–78%) and 20% (95% CI:
11–30%), respectively. On average, these patients were able to accurately name 75% of their
current regimens and 42% of their cumulative regimens.
Antiretroviral use self-report and adherence
Of the patients who provided a response to the number of doses missed within the last 3
days (n = 170), 83% reported zero-missed doses. Forty-seven percent (n = 94) of patients
reported being able to keep on a regular schedule for taking HIV medications always, 42%
(n = 85) most or some of the time, and 3% (n = 5) rarely or never. Ten percent of patients (n
= 21) did not provide a response to this question. Although not statistically significant, there
was a suggestion that patients who were always able to keep on a regular medication
schedule were more likely to be able to identify all current ARVs than patients who were not
always or never able to keep on a regular medication schedule (OR: 1.75, 95% CI: 0.79–
3.86). Conversely, patients who were always able to keep on a regular medication schedule
were less likely to be able to correctly identify all cumulative ARVs (OR: 0.68, 95% CI:
0.31–1.45).
DISCUSSION
Our results demonstrate that many HIV-infected patients are unable to recall their current
ARV regimen completely and accurately and also are unable to recall ARVs taken in past
regimens. This is particularly concerning since a complete knowledge of previous ARV
medication regimens a patient has received is essential for informing which ARVs and
regimens a patient may respond to and tolerate in the future.
Previous studies of patient recall accuracy demonstrated sensitivities between 44% and 93%;
however, these studies focused on classes of medications such as 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, anti-hypertensives, non-
steroidal anti-inflammatory agents, and hormone replacement therapy and not on individual
medications.19–22 Our sensitivities of 63% and 18% suggest that HIV-infected patients may
have more difficulty successfully recalling ARVs than patients taking other classes of
medications such as anti-hypertensives and hormone replacement therapies, which tend to
be single drug regimens.
We found that the number of ARVs a patient receives or has received in the past influences
their ability to accurately recall ARVs prescribed. This observation is expected as each new
drug added to the treatment armamentarium leads to additional complexity in an individual
regimen, generating more information that an HIV patient must remember. This is
particularly important as the number of available ARVs and ARV classes continues to
increase over time. It is likely that our findings are generalizable to other patients and
clinical conditions. Polypharmacy is common in treatment of the elderly and of other disease
states,25–28 and the inability to accurately recall current medications or a medication history
is likely a problem in these patient populations as well.
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Previous studies among HIV-positive patients have found that patients with low health
literacy and little HIV therapy knowledge are less likely to accurately identify ARV
medications.14,15,29,30 Furthermore, medication knowledge affects a patient’s ability to
adhere to medications. For example, Miller et al.15 demonstrated that a better medication
knowledge score was significantly associated with better adherence to ARVs at 8 weeks.
However, this was not seen at weeks 24 and 48 suggesting that knowledge is just one of
many factors that influence patients’ adherence to ARVs.15 While we did find that patients
who maintained a regular medication schedule were more likely to recall their current ARVs
and less likely to recall their cumulative ARVs, this association was not statistically
significant. Reasons for the observed paradoxical relationship between success at
maintaining a medication schedule could be related to behaviors of patients and the design
of the interview. Patients who are able to recall all their medications may be more honest
about their ability to maintain a schedule and report more difficulty whereas patients who
are unable to recall their medications may have greater perceived self-efficacy. We also did
not demonstrate a statistically significant association between recall and current HIV RNA
level (another marker of adherence). The presence of neurocognitive impairment in
conjunction with the complexity and cumbersome nature of medication regimens to treat
HIV may lead to difficulty recalling historical medication regimens, further supporting the
multi-faceted relationship between knowledge of HIV, recall of ARVs, and adherence. For
these reasons there is a need for additional medication reconciliation techniques targeted to
all patients who do not rely on patient memory or knowledge of HIV disease.
Our study has a few limitations. We considered the medical record as the gold standard,
which is neither a perfect measure of prescription history nor does it indicate if a patient
actually received or took the medications prescribed.31,32 Since the medical record may not
be completely accurate for patients who transferred HIV care from another facility we also
conducted analyses restricted to patients who initiated ART at our site. In these analyses, we
did not find a meaningful difference between patients followed entirely at UNC infectious
diseases clinic compared to the complete study population. Our study is also subject to recall
bias as a patient who experienced an untoward side effect to a medication (e.g., abacavir
hypersensitivity) may be more likely to recall that medication over another, resulting in
imperfect exchangeability of each ARV. However, we designed our instrument to assist the
participants with recall, by including specific ARV drug names (proprietary and generic)
and providing photographs of each ARV.33,34 Finally, the selection of patients to complete
the in-person interview was not conducted at random. Nevertheless, all patients seen in the
clinic that were consented to participate in the UNC CFAR HIV Clinical Cohort study were
approached on each selected interview day. Despite the limitations, this assessment
highlights the importance of interventions designed to enhance a patient’s awareness of their
medications, which will eventually lead to improved outcomes.
Novel tools to assist in medication reconciliation are necessary in order to reduce
dependency on patient factors, such as memory and knowledge. These instruments can be
provided to patients to maintain a personal record of ARVs and concomitant medications. At
the time of this study, the use of medication charts by HIV-positive patients was less
common than currently. Their use has continued to increase, however, a more consistent use
of these forms with the assistance of technology is needed. Making medication lists quickly
modifiable by providers and/or patients, and providing the lists in a format that is easily
maintained is important. One example is the use of USB storage devices that can be placed
on patient’s key chain, in a pocket, or in a purse and updated at each clinic visit. Another
option is a web-based personal health record (PHR). This personally controlled health record
could be modified by providers and patients. In this model the PHR is not institutionally
based, but compatible with multiple medical records systems. This way a patient can keep
information from multiple providers, over time or at various institutions, in one place and
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directly control sharing of information when necessary. While there are early projects
exploring the use of PHRs, there are challenges in implementation to be worked out and
much more evaluation necessary before they will be widely available.35 For those patients
who prefer, a paper copy of their medications in a pocket size format would be a step-wise
approach to the electronic format. Pharmacists and other providers in the clinic could work
to ensure each patient has an accurate medication history with updates for patients at each
visit. The use of these strategies would reduce the dependency on patient recall for
medication history allowing for a more accurate representation of this information in the
medical record. Interventions aimed at testing the utility of these tools within the HIV
population are needed.
In summary, this study highlights the poor reliability of patient recall in reconstructing HIV
medication histories. These findings indicate a need to implement a more consistent and
reliable method of determining medication histories as this information is critical to
providing safe and effective treatment of HIV.
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Population mean (solid line) and corresponding 95% confidence intervals (dashed line) of
self-reported accuracy (number of correct self-reported ARVs also in the clinical record
divided by the number of ARVs in the clinical record) by number of ARVs patients were
taking at the time of the interview (current) and all ARVs recorded in the medical record at
the time of the interview (ever)
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Table 1
Patient demographic and clinical characteristics for the study population and the UNC-CFAR HIV Clinical
Cohort
Characteristics Study population (n = 205) Cohort (n = 1840)
Female, n (%) 70 (34) 582 (32)
African-American, n (%) 144 (70) 1094 (59)
Injection drug use, n (%) 42 (20) 278 (15)
Men who have sex with men, n (%) 77 (38) 674 (36)
Peak HIV RNA log10 (copies/ml), median (IQR) 5.0 (4.4–5.9) 5.0 (4.4–5.6)
Nadir CD4 cell count (cells/μl), median (IQR) 159 (37–325) 134 (28–288)
Patient characteristics at the time of interview
Age, median (IQR) 42 (36–47) N/A
Education <12 years, n (%) 73 (36) N/A
Current HIV RNA <400 copies/ml, n (%) 98 (48) N/A
Current CD4 cell count (cells/μl), median (IQR) 407 (228–620) N/A
Number of prior ARVs, median (IQR) 5 (2–7) N/A
Years in HIV care, median (IQR) 6.7 (3.9–9.5) N/A
ARV, antiretroviral; IQR, interquartile range; N/A, not available/applicable.
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